These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38803161)

  • 1. Proteomics of tumor and serum samples from isocitrate dehydrogenase-wildtype glioblastoma patients: is the detoxification of reactive oxygen species associated with shorter survival?
    Clavreul A; Guette C; Lasla H; Rousseau A; Blanchet O; Henry C; Boissard A; Cherel M; Jézéquel P; Guillonneau F; Menei P; Lemée JM
    Mol Oncol; 2024 May; ():. PubMed ID: 38803161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide.
    Clavreul A; Lemée JM; Soulard G; Rousseau A; Menei P
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
    Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
    Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
    Jiang H; Yu K; Cui Y; Ren X; Li M; Zhang G; Yang C; Zhao X; Zhu Q; Lin S
    Front Oncol; 2021; 11():632663. PubMed ID: 34055603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
    Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
    Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?
    Clavreul A; Autier L; Lemée JM; Augereau P; Soulard G; Bauchet L; Figarella-Branger D; Menei P; Network F;
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.
    Sommerlath VN; Buergy D; Etminan N; Brehmer S; Reuss D; Sarria GR; Guiot MC; Hänggi D; Wenz F; Petrecca K; Giordano FA
    Radiat Oncol; 2022 Jan; 17(1):15. PubMed ID: 35073955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
    van der Meulen M; Ramos RC; Voisin MR; Patil V; Wei Q; Singh O; Climans SA; Kalidindi N; Or R; Aldape K; Diamandis P; Munoz DG; Zadeh G; Mason WP
    Neurooncol Adv; 2024; 6(1):vdae001. PubMed ID: 38312227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated genomic analysis of survival outliers in glioblastoma.
    Peng S; Dhruv H; Armstrong B; Salhia B; Legendre C; Kiefer J; Parks J; Virk S; Sloan AE; Ostrom QT; Barnholtz-Sloan JS; Tran NL; Berens ME
    Neuro Oncol; 2017 Jun; 19(6):833-844. PubMed ID: 27932423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
    Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
    Hertler C; Felsberg J; Gramatzki D; Le Rhun E; Clarke J; Soffietti R; Wick W; Chinot O; Ducray F; Roth P; McDonald K; Hau P; Hottinger AF; Reijneveld J; Schnell O; Marosi C; Glantz M; Darlix A; Lombardi G; Krex D; Glas M; Reardon DA; van den Bent M; Lefranc F; Herrlinger U; Razis E; Carpentier AF; Phillips S; Rudà R; Wick A; Tabouret E; Meyronet D; Maurage CA; Rushing E; Rapkins R; Bumes E; Hegi M; Weyerbrock A; Aregawi D; Gonzalez-Gomez C; Pellerino A; Klein M; Preusser M; Bendszus M; Golfinopoulos V; von Deimling A; Gorlia T; Wen PY; Reifenberger G; Weller M
    Eur J Cancer; 2023 Aug; 189():112913. PubMed ID: 37277265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteins inform survival-based differences in patients with glioblastoma.
    Stetson LC; Ostrom QT; Schlatzer D; Liao P; Devine K; Waite K; Couce ME; Harris PLR; Kerstetter-Fogle A; Berens ME; Sloan AE; Islam MM; Rajaratnam V; Mirza SP; Chance MR; Barnholtz-Sloan JS
    Neurooncol Adv; 2020; 2(1):vdaa039. PubMed ID: 32642694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
    Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    Neurosurg Rev; 2018 Apr; 41(2):621-628. PubMed ID: 28887717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma.
    Ofek P; Yeini E; Arad G; Danilevsky A; Pozzi S; Luna CB; Dangoor SI; Grossman R; Ram Z; Shomron N; Brem H; Hyde TM; Geiger T; Satchi-Fainaro R
    Int J Cancer; 2023 Aug; 153(3):654-668. PubMed ID: 37141410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.
    Rosager AM; Dahlrot RH; Sørensen MD; Bangsø JA; Hansen S; Kristensen BW
    J Neuropathol Exp Neurol; 2022 Jan; 81(1):54-60. PubMed ID: 34875075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.